Navigation Links
ValGenesis, Inc. Announces Worldwide Release of Validation Life Cycle Management System - ValGenesis 2.0
Date:6/26/2008

FREMONT, Calif., June 26 /PRNewswire/ -- ValGenesis, Inc., a leading provider of Enterprise Validation Management software solutions, announced the worldwide availability of ValGenesis 2.0, the latest version of its breakthrough Web-based, multi-site, scalable validation life cycle management and automation product.

Life science companies implementing the ValGenesis software suite can efficiently manage the entire validation life cycle and move securely from manual, paper-based validation processes to a 100 percent paperless, fully electronic validation process. ValGenesis enforces consistency and enhances compliance in the corporate validation process. Users see a holistic view of a company's validation status and are able to identify bottlenecks, reducing validation cycle time and cost by 40 to 50 percent.

An out-of-the-box solution, with template-driven rapid implementation methodology requiring less overall implementation and validation time, this allows ValGenesis clients' Information Technology and Validation personnel to easily manage other projects in parallel. Among the enhancements in ValGenesis 2.0 are improved requirements management, expanded traceability matrix capability, risk assessment, offline validation execution, workflow design and collaboration through the robust library module.

ValGenesis 2.0 features the ability to implement a single validation system for all corporate/site validation requirements. A centralized deployment provides easier maintenance. By providing 360-degree visibility to the validation process, communication among all cross-functional users is significantly enhanced, while internal and external audit preparation time is reduced by 90 percent. End-users can easily personalize the web-based interface to their needs and interest.

"ValGenesis 2.0 includes substantial technological advancements, enhances the team-based review and can be hosted at a single location and deployed globally in order to address our customers' increasing need for collaboration in today's stringently regulated marketplace," said Siva Samy, PhD, ValGenesis Chief Product Strategist. "We have incorporated several new features and enhancements based on recommendations from our customers which allow our new customers to fully address their core validation requirements and expedite the validation process while remaining fully compliant with industry regulations." He added, "This version introduces the first phase of our new integration initiative. We've partnered with leading companies in the content management and ERP sectors to provide fully integrated solutions." Samy said, "We are particularly excited about the potential for significant savings to our clients using this version's global validation capabilities in which reviewers, approvers and engineers (developers and testers) can share and review information from different locations simultaneously."

About ValGenesis

ValGenesis offers an innovative software platform that serves as the foundation for compliance-based validation life cycle management in regulated companies. ValGenesis is the first Enterprise application to automate the validation life cycle of GxP systems and to provide 360-degree visibility to the corporate validation process. ValGenesis is designed to fully conform to FDA 21 CFR Part 11 compliance requirements. Through an industry peer review committee, the Parenteral Drug Association (PDA) awarded ValGenesis the prestigious New Innovative Technology award.

For more information, visit ValGenesis's web site at http://www.valgenesis.com.

Press Contact:

Mike Beaudro

Marketing Manager

Beaudro@valgenesis.com

Ph: 510 445 0505

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE ValGenesis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Mich. , Dec. 7, 2016 Neogen ... has named Dr. Dan Kephart as its ... company. Kephart will assume his responsibilities at Neogen effective ... and development director for the agribusiness unit of Thermo ... safety development at Life Technologies. His extensive industry experience ...
(Date:12/7/2016)... CALGARY , Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ... update that will be presented at the Company,s Annual and ... Meeting of Shareholders will take place on Thursday, December 15, ... Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate ... am (MST). A notice of meeting and management information circular, ...
(Date:12/7/2016)... Dec. 7, 2016  Biocom, the association for the ... below following passage of 21 st Century Cures legislation ... 30 by a 392-26 vote and in the Senate on ... attributed to Joe Panetta , president & CEO of ... give hope to millions of patients around the world. The ...
(Date:12/7/2016)... , Dec. 7, 2016  Vyriad Inc. announced ... to the company,s Board of Directors. "We ... we build our business and develop our oncolytic viruses ... therapy," said Stephen Russell , MD, PhD, CEO ... , share our vision and passion for making a ...
Breaking Biology Technology:
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is ... analysis for Private Biobanks shows the highest Compounded Annual Growth ... region during the analysis period 2014-2020. ... CAGR of 9.95% followed by Europe ...
(Date:11/16/2016)... Calif. , Nov. 16, 2016 ... user experience and security for consumer electronics, and ... the financial and retail industry, today announced a ... and convenient way to authenticate users of mobile ... Sensory,s TrulySecure™ software which requires no ...
Breaking Biology News(10 mins):